Anacor Pharmaceutical
Palo Alto
About Anacor Pharmaceutical
Anacor Pharmaceuticals is a biopharmaceutical company that engages in developing small-molecule therapeutics from its boron chemistry platform. It focuses on developing topical applications of its compounds to treat fungal, bacterial, and inflammatory diseases. The company’s primary product candidate, AN2690, is a novel topical antifungal for the treatment of toenail onychomycosis, a fungal infection of the nail and nail bed. It is also developing AN2728, an anti-inflammatory product candidate for the treatment of psoriasis; AN0128, a product candidate that has antibiotic and anti-inflammatory properties; and AN2718, which is in preclinical development for the topical treatment of vaginal candidiasis and tineapedis.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Delisted
- Employees: 51 – 100
- Estimated revenue: $50K – $100K
- Total funding: $448.4M
- Funding stage: M&A
- Last round: Post-IPO Debt (Apr 2016)
- Ticker: nasdaq:ANAC
- Website: anacor.com
- Phone: (650) 543-7500
Industries & Categories
Biotechnology, Health Care, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/anacor-pharmaceutical-27298 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.